Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

329

Participants

Timeline

Start Date

July 17, 2020

Primary Completion Date

March 31, 2026

Study Completion Date

December 31, 2026

Conditions
Urinary Bladder NeoplasmTriple Negative Breast NeoplasmsHormone Receptor Positive, HER2-negative NeoplasmsHormone Receptor Positive, HER2-low NeoplasmsBreast NeoplasmsNon-Small-Cell Lung NeoplasmsOvarian NeoplasmAdvanced Solid Tumor
Interventions
DRUG

BT8009

Bicyclic Toxin Conjugate (BTC) administered either weekly (i.e., on Days 1, 8, 15, and 22) or biweekly (Days 1 and 15) on a 28-day cycle or on Days 1 and 8 of a 21-day cycle for participants in A-1. Participants in Cohorts A-2 and B-7 will receive BT8009 weekly on 21-day cycle. Participants in Parts B-1-B-6 will receive BT8009 weekly either on a 21-day or 28-day cycle. Participants in Parts B-8 and B-9 will receive BT8009 on Days 1 and 8 of a 21-day cycle. Participants in Cohort C will receive BT8009 once weekly (i.e., on Days 1, 8, 15, and 22) on a 28-day cycle. Participants in Part D will receive BT8009 once weekly on a 28-day cycle.

DRUG

Pembrolizumab

Participants in Cohorts A-2 and B-7 will receive 200 mg IV over 30-minute infusion of pembrolizumab on Day 1 of each Q3W.

Trial Locations (29)

10029

RECRUITING

Icahn School of Medicine at Mount Sinai, New York

13009

RECRUITING

Institut Paoli-Calmettes, Marseille

19107

RECRUITING

Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia

20132

RECRUITING

Ospedale San Raffaele, Milan

20133

RECRUITING

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan

28040

RECRUITING

START Madrid Fundacion Jimenez Diaz, Madrid

28046

WITHDRAWN

Hospital Universitario La Paz, Madrid

28223

RECRUITING

Next Oncology - Hospital Quironsalud Madrid, Pozuelo de Alarcón

33076

RECRUITING

Institut Bergonie, Bordeaux

34474

RECRUITING

Ocala Oncology Center, Ocala

34747

RECRUITING

Advent Health, Orlando

35042

RECRUITING

Centre Eugene Marquis, Rennes

37203

RECRUITING

Tennessee Oncology, PLLC, Nashville

39008

RECRUITING

Hospital Universitario Marques de Valdecilla, Santander

40207

WITHDRAWN

Norton Cancer Institute, Downtown, Louisville

44106

RECRUITING

University Hospitals Cleveland Medical Center, Cleveland

47905

WITHDRAWN

Horizon Oncology Research, Lafayette

69373

RECRUITING

Centre Leon Berard, Lyon

75230

RECRUITING

Mary Crowley Cancer Research Center, Dallas

77030

RECRUITING

The University of Texas MD Anderson Cancer Center, Houston

80218

RECRUITING

Sarah Cannon Research Institute at HealthONE, Denver

89169

WITHDRAWN

Comprehensive Cancer Centers of Nevada, Las Vegas

94805

RECRUITING

Institut Gustave Roussy, Villejuif

T6G 1Z2

WITHDRAWN

Cross Cancer Institute, Edmonton

M5G IZ5

RECRUITING

University Health Network, Princess Margaret Cancer Centre, Toronto

08035

RECRUITING

Vall d'Hebron Institute of Oncology, Barcelona

08036

RECRUITING

Hospital Clinic de Barcelona, Barcelona

W1G 6AD

RECRUITING

Sarah Cannon Research Institute UK, London

M20 4BX

RECRUITING

The Christie NHS Foundation Trust, Manchester

All Listed Sponsors
lead

BicycleTx Limited

INDUSTRY